Company research
ABBOTT LABORATORIES
CIK 1800Updated Sep 24, 2026
SecurityABT · NYSE · equity
ABT price & chart
Loading TradingView…
NYSE:ABT on TradingView ↗About the company
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, and on LinkedIn, Facebook, Instagram, X and YouTube.
In the news
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments News provided by Abbott Nov 20, 2025, 07:30 ET Share this article Share to X Share this article Share to X Acquisition adds a new growth vertical to Abbott's already high ↗
Recent filings
144 filing
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 86,713,000,000Source | 81,414,000,000Source | 73,214,000,000Source | 74,438,000,000Source |
| Property, Plant and Equipment, NetUSD | 11,816,000,000Source | 10,658,000,000Source | 10,154,000,000Source | 9,162,000,000Source |
| GoodwillUSD | 24,035,000,000Source | 23,108,000,000Source | 23,679,000,000Source | 22,799,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 5,526,000,000Source | 6,647,000,000Source | 8,815,000,000Source | 10,454,000,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,522,000,000Source | 7,616,000,000Source | 6,896,000,000Source | 9,882,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 7,929,000,000Source | 6,925,000,000Source | 6,565,000,000Source | 6,218,000,000Source |
| Inventory, NetUSD | 6,488,000,000Source | 6,194,000,000Source | 6,570,000,000Source | 6,173,000,000Source |
| Assets, CurrentUSD | 25,996,000,000Source | 23,656,000,000Source | 22,670,000,000Source | 25,224,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,126,000,000Source | 1,075,000,000Source | 1,122,000,000Source | 1,116,000,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 25,527,000,000Source | 25,153,000,000Source | 24,869,000,000Source | 24,709,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | 49,781,000,000Source | 47,261,000,000Source | 37,554,000,000Source | 35,257,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,001,000,000Source | -7,906,000,000Source | -7,839,000,000Source | -8,051,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 52,130,000,000Source | 47,664,000,000Source | 38,603,000,000Source | 36,686,000,000Source |
| Liabilities and EquityUSD | 86,713,000,000Source | 81,414,000,000Source | 73,214,000,000Source | 74,438,000,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,496,000,000Source | 14,157,000,000Source | 13,841,000,000Source | 15,489,000,000Source |
| Operating Lease, Liability, CurrentUSD | 276,000,000Source | 254,000,000Source | 245,000,000Source | 230,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 931,000,000Source | 896,000,000Source | 949,000,000Source | 943,000,000Source |
| Other Liabilities, NoncurrentUSD | 2,538,000,000Source | 3,443,000,000Source | 3,466,000,000Source | 3,804,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 641,000,000Source | 237,000,000Source | 224,000,000Source | 219,000,000Source |
| Additional Financial Items | ||||
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | 1,000,000Source | 611,000,000Source | 1,376,000,000Source | 1,493,000,000Source |
| Dividends Payable, CurrentUSD | 1,097,000,000Source | 1,024,000,000Source | 955,000,000Source | 887,000,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 3,033,000,000Source | 1,500,000,000Source | 1,080,000,000Source | 2,251,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,896,000,000Source | 12,625,000,000Source | 13,599,000,000Source | 14,522,000,000Source |
| Short-term InvestmentsUSD | 417,000,000Source | 351,000,000Source | 383,000,000Source | 288,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 664,000,000Source | 673,000,000Source | 644,000,000Source | 685,000,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 652,000,000Source | 691,000,000Source | 356,000,000Source | 68,000,000Source |
| Increase (Decrease) in InventoriesUSD | -195,000,000Source | 58,000,000Source | 232,000,000Source | 1,413,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | 441,000,000Source | -7,961,000,000Source | -461,000,000Source | -659,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 9,566,000,000Source | 8,558,000,000Source | 7,261,000,000Source | 9,581,000,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,422,000,000Source | -2,338,000,000Source | -3,133,000,000Source | -1,740,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -18,000,000Source | -9,000,000Source | -22,000,000Source | -22,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,171,000,000Source | 2,207,000,000Source | 2,202,000,000Source | 1,777,000,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 893,000,000Source | 1,295,000,000Source | 1,227,000,000Source | 3,795,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -6,309,000,000Source | -5,404,000,000Source | -7,091,000,000Source | -7,636,000,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 4,116,000,000Source | 3,836,000,000Source | 3,556,000,000Source | 3,309,000,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -82,000,000Source | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 906,000,000Source | 720,000,000Source | -2,986,000,000Source | 83,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,522,000,000Source | 7,616,000,000Source | 6,896,000,000Source | 9,882,000,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 545,000,000Source | 604,000,000Source | 662,000,000Source | 563,000,000Source |
| Income Taxes Paid, NetUSD | 1,933,000,000Source | 1,723,000,000Source | 1,475,000,000Source | 1,864,000,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 664,000,000Source | 673,000,000Source | 644,000,000Source | 685,000,000Source |
| Amortization of Intangible AssetsUSD | 1,682,000,000Source | 1,878,000,000Source | 1,966,000,000Source | 2,013,000,000Source |
| DepreciationUSD | 1,434,000,000Source | 1,340,000,000Source | 1,277,000,000Source | 1,254,000,000Source |
| Dividends Payable, CurrentUSD | 1,097,000,000Source | 1,024,000,000Source | 955,000,000Source | 887,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 50,000,000Source | 27,000,000Source | -41,000,000Source | -2,000,000Source |
| GoodwillUSD | 24,035,000,000Source | 23,108,000,000Source | 23,679,000,000Source | 22,799,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 111,000,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 6,933,000,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 1,942,000,000Source | -6,389,000,000Source | 941,000,000Source | 1,373,000,000Source |
| InterestExpenseNonoperatingUSD | 493,000,000Source | 559,000,000Source | — | — |
| Investment Income, InterestUSD | 308,000,000Source | 344,000,000Source | 385,000,000Source | 183,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 6,524,000,000Source | 13,402,000,000Source | 5,723,000,000Source | 6,933,000,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 6,500,000,000Source | 13,351,000,000Source | 5,701,000,000Source | 6,905,000,000Source |
| Other Nonoperating Income (Expense)USD | 548,000,000Source | 376,000,000Source | 479,000,000Source | 321,000,000Source |
| Payments to Acquire InvestmentsUSD | 167,000,000Source | 169,000,000Source | 159,000,000Source | 185,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 396,000,000Source | 264,000,000Source | 167,000,000Source | 167,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 44,328,000,000Source | 41,950,000,000Source | 40,109,000,000Source | 43,653,000,000Source |
| Cost of RevenueUSD | 19,319,000,000Source | 18,706,000,000Source | 17,975,000,000Source | 19,142,000,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 12,332,000,000Source | 11,697,000,000Source | 10,949,000,000Source | 11,248,000,000Source |
| Operating Income (Loss)USD | 8,053,000,000Source | 6,825,000,000Source | 6,478,000,000Source | 8,362,000,000Source |
| Other Nonoperating Income (Expense)USD | 548,000,000Source | 376,000,000Source | 479,000,000Source | 321,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 8,466,000,000Source | 7,013,000,000Source | 6,664,000,000Source | 8,306,000,000Source |
| Income Tax Expense (Benefit)USD | 1,942,000,000Source | -6,389,000,000Source | 941,000,000Source | 1,373,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 6,524,000,000Source | 13,402,000,000Source | 5,723,000,000Source | 6,933,000,000Source |
| Earnings Per Share, BasicUSD per share | 3.73Source | 7.67Source | 3.28Source | 3.94Source |
| Earnings Per Share, DilutedUSD per share | 3.72Source | 7.64Source | 3.26Source | 3.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,741,000,000Source | 1,740,000,000Source | 1,740,000,000Source | 1,753,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,748,000,000Source | 1,748,000,000Source | 1,749,000,000Source | 1,764,000,000Source |
| Interest Expense (non-operating)USD | 493,000,000Source | 559,000,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,682,000,000Source | 1,878,000,000Source | 1,966,000,000Source | 2,013,000,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 2.4Source | 2.24Source | — | — |
| Costs and ExpensesUSD | 36,275,000,000Source | 35,125,000,000Source | 33,631,000,000Source | 35,291,000,000Source |
| Current Income Tax Expense (Benefit)USD | 1,501,000,000Source | 1,572,000,000Source | 1,402,000,000Source | 2,032,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 50,000,000Source | 27,000,000Source | -41,000,000Source | -2,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,762,000,000Source | 947,000,000Source | 1,192,000,000Source | 3,732,000,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 6,933,000,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | 3.94Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | 3.91Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Interest ExpenseUSD | — | — | 637,000,000Source | 558,000,000Source |
| Investment Income, InterestUSD | 308,000,000Source | 344,000,000Source | 385,000,000Source | 183,000,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 6,500,000,000Source | 13,351,000,000Source | 5,701,000,000Source | 6,905,000,000Source |
| Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost ComponentUSD | 590,000,000Source | 542,000,000Source | 498,000,000Source | 406,000,000Source |
| Research and Development ExpenseUSD | 2,942,000,000Source | 2,844,000,000Source | 2,741,000,000Source | 2,888,000,000Source |
Filing attachments
tm2623675d1_ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 tm2623675d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evi…
Read attachment ↗tm2611915d1_ex99-1.htm · 8-K · 2026-04-17
EX-99.1 2 tm2611915d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -------------------------------------------------------x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATION CASE NO: 1:22-cv-5513 Hon. Sunil R. Harjani Hon. Laura K. McNally -------------------------------------------------------x NOTICE OF PROPOSED SETTLEMENT OF CONSOLIDATED DERIVATIVE ACTION, FINAL SETTLE…
Read attachment ↗tm268709d2_ex99-1.htm · 8-K · 2026-03-23
EX-99.1 2 tm268709d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Abbott completes acquisition of Exact Sciences Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott’s mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 - Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-g…
Read attachment ↗tm264905d8_ex4-2.htm · 8-K · 2026-03-09
EX-4.2 2 tm264905d8_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Execution Version ABBOTT LABORATORIES OFFICERS’ CERTIFICATE PURSUANT TO SECTIONS 3.1 AND 3.3 OF THE INDENTURE The undersigned, Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer of Abbott Laboratories (“Abbott” or the “Company”), and James R. Wenner, Vice President, Treasurer of the Company, hereby certify, pursuant to (i) Sections 3.1 and 3.3 of the Indenture, dated as of March 10, 2015 (as it may from …
Read attachment ↗tm2533113d1_ex99-1.htm · 8-K · 2025-12-12
EX-99.1 2 tm2533113d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 12, 2025 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may have such other offices either within or without the State of I…
Read attachment ↗tm2531676d1_ex99-1.htm · 8-K · 2025-11-21
EX-99.1 2 tm2531676d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notice of Blackout Period to Directors and Executive Officers of Abbott Laboratories This notice explains certain restrictions on your investments in securities of Abbott Laboratories (“Abbott”) during an upcoming retirement plan blackout period. As a director or executive officer of Abbott, you are subject to restrictions under Section 306(a) of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”) and Rule 104 of Regulation BTR unde…
Read attachment ↗